FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Published Online: Wednesday, December 19, 2012
Follow Pharmacy_Times:
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.
Related Articles
Self-monitoring is an effective method for hypertensive patients who are at risk for cardiovascular comorbidity.
Providing prescriptions when patients are discharged from the hospital after a stroke improves medication adherence, the results of a study suggest.
Aspirin may reduce the risk of blood clots in patients who cannot use traditional anticoagulants, new research suggests.
Statin guidelines released jointly by the American Heart Association and the American College of Cardiology more accurately identify patients with heavy arterial plaque buildup for therapy.
Latest Issues
$auto_registration$